Consumer Must-Know: How PBM Transparency Rules Could Reshape Drug Pricing

What the CMS Proposal to Repeal Breakthrough Device Payments Means for Patient Access

Update The CMS Proposal: Impacts on Breakthrough Medical Devices The Centers for Medicare and Medicaid Services (CMS) has proposed a significant change to the way breakthrough medical devices are compensated. Starting in fiscal year 2028, the CMS will repeal the alternative payment pathway that allowed certain innovative devices to receive additional financial support without the need to demonstrate substantial clinical improvement. Previously, medical devices designated as breakthrough could qualify for New Technology Add-On Payments (NTAP) if they met criteria regarding their innovation and cost. Now, the proposal requires that these devices prove they substantially improve existing treatments, a shift expected to affect the speed and scope of innovation in the medical technology sector. Why Does This Matter for Consumers? This change could have a direct impact on patients seeking advanced treatment options. For consumers, especially those with chronic conditions, having access to new technologies hinges on the availability of funding for medical providers to implement these innovations. When hospitals are unable to cover costs for new devices, patients may find themselves relying on outdated treatments that do not meet their needs. The CMS argues that requiring significant clinical proof will enable better decision-making and ensure that only the most effective technologies receive taxpayer support. However, stakeholders like AdvaMed, a major industry trade group, express concerns that this proposal could hinder medical progress—particularly for small medtech firms that may struggle under stricter evaluation criteria. Historical Context of Breakthrough Device Designation The FDA introduced the breakthrough device pathway to expedite patient access to innovative medical treatments for life-threatening conditions. To date, 1,226 devices have received this designation since its inception. In the past, this pathway allowed for quicker reimbursement processes, which encouraged innovation and provided patients with timely access to advanced treatments. The existing system that will now be curtailed has allowed many small companies and innovators to thrive, fostering a competitive environment that benefits the healthcare industry as a whole. The proposal to withdraw this flexibility signals potential barriers that could stifle the development of new, life-saving technologies. Looking Towards the Future: Potential Outcomes The implications of repealing the add-on payment pathway are vast. While the CMS’s intention to solidify evaluation standards is noteworthy, experts are concerned it may inadvertently slow down innovation. If emerging technologies face increased scrutiny and a rigorous proof-of-value requirement, we may see fewer innovative solutions entering the market—especially those from smaller companies that lack the resources to navigate the complex reimbursement landscape. This policy shift raises critical questions about balancing public health needs with fiscal responsibility. Will the effort to ensure all new technologies provide substantial improvements lead to unintended delays in patient access to potentially life-saving treatments? Consumers must stay informed about these changes, understanding how they can affect healthcare choices and access to innovative treatments.